Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Christian W JohnsonDeborah L BurkhartKevin M HaigisPublished in: Cancer discovery (2022)
Efforts in the recent past to inhibit KRAS oncogenicity have focused on kinases that function in downstream signal transduction cascades, although preclinical successes have not translated to patients with KRAS-mutant cancer. Recently, clinically effective covalent inhibitors of KRASG12C have been developed, establishing two principles that form a foundation for future efforts. First, KRAS is druggable. Second, each mutant form of KRAS is likely to have properties that make it uniquely druggable.